This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Three Best Genomics Stocks for Your Portfolio in 2026
by Ekta Bagri
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
ILMNPositive Net Change BEAMNegative Net Change PACBPositive Net Change CRSPPositive Net Change CRBUNegative Net Change WGSPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetic-testing genomics medical pharmaceuticals
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
by Zacks Equity Research
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
REGNPositive Net Change SNYNegative Net Change INDVPositive Net Change
biotechs
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
by Sundeep Ganoria
ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treatments.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
by Zacks Equity Research
ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.
ANIPPositive Net Change IBRXNegative Net Change INDVPositive Net Change
biotechs
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
by Zacks Equity Research
Eli Lilly launches oral GLP-1 pill Foundayo, pairing low-cost access with Amazon and GoodRx partnerships to challenge rivals in the fast-growing obesity market.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
by Zacks Equity Research
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.
GILDPositive Net Change KYMRPositive Net Change INDVPositive Net Change
biotechs
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
by Kinjel Shah
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
TEVAPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechs
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
by Kinjel Shah
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
TEVAPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechs
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
by Kinjel Shah
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
TEVAPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechs